Aside from reducing hyperglycemia and increasing insulin sensitivity, several other beneficial clinical effects have been reported for SGLT-2 inhibitors, including reduced risks of cardiovascular and renal diseases, improved blood pressure control, body weight reduction, and reductions in liver fat content (34–37). This evidence concerns the gene SLC5A2 and Hyperglycemia.